CCL2 and graft versus host disease: However, gene expression variations could result in different responses among MSC groups treated with INFγ, and these immunomodulation related genes were mainly in the shared regulation networks, including abovementioned TNSF10, CXCL9, CXCL10, CXCL11, and CCL2. Furthermore, human MSCs licensed by INFγ have been tested in NOD-SCID mice showing enhanced immunosuppressive properties to significantly reduce the symptoms of GvHD [61], indicating potential clinical application of INFγ primed MSCs.